65/100 · Elevated
Manufactured by Noven Therapeutics, LLC
Methylphenidate Adverse Events: Moderate Safety Concerns
63,290 FDA adverse event reports analyzed
Last updated: 2026-05-12
METHYLPHENIDATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Noven Therapeutics, LLC. Based on analysis of 63,290 FDA adverse event reports, METHYLPHENIDATE has a safety score of 65 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for METHYLPHENIDATE include NO ADVERSE EVENT, OFF LABEL USE, PRODUCT QUALITY ISSUE, DRUG INEFFECTIVE, DRUG ADMINISTRATION ERROR. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METHYLPHENIDATE.
Methylphenidate has a safety concern score of 65 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 63,290 adverse event reports for this medication, which is primarily manufactured by Noven Therapeutics, Llc.
The most commonly reported adverse events include No Adverse Event, Off Label Use, Product Quality Issue. Of classified reports, 36.7% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. The majority of adverse events are non-serious, but serious events account for a significant portion of reports.
Psychiatric and neurological side effects are common, including anxiety, depression, and aggression. Drug interactions and administration errors are frequent, highlighting the need for careful handling. Weight changes and gastrointestinal issues are also reported, affecting patient quality of life.
Patients taking Methylphenidate should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Methylphenidate can interact with other medications, and administration errors are common. Healthcare providers should be cautious and monitor patients closely. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Methylphenidate received a safety concern score of 65/100 (elevated concern). This is based on a 36.7% serious event ratio across 27,919 classified reports. The score accounts for 63,290 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Male: 12,025, Female: 9,827, Unknown: 306. The most frequently reported age groups are age 9 (738 reports), age 8 (670 reports), age 10 (655 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 27,919 classified reports for METHYLPHENIDATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Methylphenidate can interact with other medications, and administration errors are common. Healthcare providers should be cautious and monitor patients closely.
If you are taking Methylphenidate, here are important things to know. The most commonly reported side effects include no adverse event, off label use, product quality issue, drug ineffective, drug administration error. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Follow prescribed dosages and administration instructions carefully to avoid drug interactions and errors. Report any serious or unusual side effects to your healthcare provider immediately. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor Methylphenidate safety. Patients should report any adverse events to their healthcare provider and the FDA.
The FDA has received approximately 63,290 adverse event reports associated with Methylphenidate. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Methylphenidate include No Adverse Event, Off Label Use, Product Quality Issue, Drug Ineffective, Drug Administration Error. By volume, the top reported reactions are: No Adverse Event (6,875 reports), Off Label Use (5,881 reports), Product Quality Issue (5,241 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Methylphenidate.
Out of 27,919 classified reports, 10,254 (36.7%) were classified as serious and 17,665 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Methylphenidate break down by patient sex as follows: Male: 12,025, Female: 9,827, Unknown: 306. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Methylphenidate adverse events are: age 9: 738 reports, age 8: 670 reports, age 10: 655 reports, age 7: 637 reports, age 11: 553 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Methylphenidate adverse event reports is Noven Therapeutics, Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Methylphenidate include: Wrong Technique In Drug Usage Process, Application Site Erythema, Drug Dose Omission, Incorrect Drug Administration Duration, Wrong Technique In Product Usage Process. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Methylphenidate to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Methylphenidate has a safety concern score of 65 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. The majority of adverse events are non-serious, but serious events account for a significant portion of reports.
Key safety signals identified in Methylphenidate's adverse event data include: Over 10,000 serious adverse events reported, comprising a significant portion of total reports.. Psychiatric disturbances such as anxiety, depression, and aggression are key safety signals.. Drug administration errors and interactions are frequent, indicating potential misuse or improper handling.. Weight changes and gastrointestinal issues are notable, suggesting potential metabolic and digestive side effects.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Methylphenidate can interact with other medications, and administration errors are common. Healthcare providers should be cautious and monitor patients closely. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Methylphenidate.
Follow prescribed dosages and administration instructions carefully to avoid drug interactions and errors. Report any serious or unusual side effects to your healthcare provider immediately.
Methylphenidate has 63,290 adverse event reports on file with the FDA. Psychiatric and neurological side effects are common, including anxiety, depression, and aggression. The volume of reports for Methylphenidate reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor Methylphenidate safety. Patients should report any adverse events to their healthcare provider and the FDA. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
The following drugs share commonly reported adverse reactions with METHYLPHENIDATE:
Drugs related to METHYLPHENIDATE based on therapeutic use, drug class, or shared indications: